Abstract | BACKGROUND: METHODS: In the DECLARE-TIMI 58 trial, baseline heart failure (HF) status was collected from all patients, and EF was collected when available. HF with reduced EF (HFrEF) was defined as EF <45%. Outcomes of interest were the composite of cardiovascular death/HHF, its components, and all-cause mortality. RESULTS: Of 17 160 patients, 671 (3.9%) had HFrEF, 1316 (7.7%) had HF without known reduced EF, and 15 173 (88.4%) had no history of HF at baseline. Dapagliflozin reduced cardiovascular death/HHF more in patients with HFrEF (hazard ratio [HR], 0.62 [95% CI, 0.45-0.86]) than in those without HFrEF (HR, 0.88 [95% CI, 0.76-1.02]; P for interaction=0.046), in whom the treatment effect of dapagliflozin was similar in those with HF without known reduced EF (HR, 0.88 [95% CI, 0.66-1.17]) and those without HF (HR, 0.88 [95% CI, 0.74-1.03]). Whereas dapagliflozin reduced HHF both in those with (HR, 0.64 [95% CI, 0.43-0.95]) and in those without HFrEF (HR, 0.76 [95% CI, 0.62-0.92]), it reduced cardiovascular death only in patients with HFrEF (HR, 0.55 [95% CI, 0.34-0.90]) but not in those without HFrEF (HR, 1.08 [95% CI, 0.89-1.31]; P for interaction=0.012). Likewise, dapagliflozin reduced all-cause mortality in patients with HFrEF (HR, 0.59 [95% CI, 0.40-0.88;) but not in those without HFrEF (HR, 0.97 [95% CI, 0.86-1.10]; P for interaction=0.016). CONCLUSIONS: CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01730534.
|
Authors | Eri T Kato, Michael G Silverman, Ofri Mosenzon, Thomas A Zelniker, Avivit Cahn, Remo H M Furtado, Julia Kuder, Sabina A Murphy, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc P Bonaca, Christian T Ruff, Akshay S Desai, Shinya Goto, Peter A Johansson, Ingrid Gause-Nilsson, Per Johanson, Anna Maria Langkilde, Itamar Raz, Marc S Sabatine, Stephen D Wiviott |
Journal | Circulation
(Circulation)
Vol. 139
Issue 22
Pg. 2528-2536
(05 28 2019)
ISSN: 1524-4539 [Electronic] United States |
PMID | 30882238
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzhydryl Compounds
- Cardiovascular Agents
- Glucosides
- Sodium-Glucose Transporter 2 Inhibitors
- dapagliflozin
|
Topics |
- Aged
- Benzhydryl Compounds
(adverse effects, therapeutic use)
- Cardiovascular Agents
(adverse effects, therapeutic use)
- Cause of Death
- Diabetes Mellitus, Type 2
(diagnosis, drug therapy, mortality)
- Double-Blind Method
- Female
- Glucosides
(adverse effects, therapeutic use)
- Heart Failure
(diagnosis, drug therapy, mortality, physiopathology)
- Humans
- Male
- Middle Aged
- Risk Assessment
- Risk Factors
- Sodium-Glucose Transporter 2 Inhibitors
(adverse effects, therapeutic use)
- Stroke Volume
(drug effects)
- Time Factors
- Treatment Outcome
- Ventricular Function, Left
(drug effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|